These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

442 related items for PubMed ID: 31663736

  • 1. Heat Shock Protein 90 Inhibitors: An Update on Achievements, Challenges, and Future Directions.
    Li L, Wang L, You QD, Xu XL.
    J Med Chem; 2020 Mar 12; 63(5):1798-1822. PubMed ID: 31663736
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. Blocking the chaperone kinome pathway: mechanistic insights into a novel dual inhibition approach for supra-additive suppression of malignant tumors.
    Grover A, Shandilya A, Agrawal V, Pratik P, Bhasme D, Bisaria VS, Sundar D.
    Biochem Biophys Res Commun; 2011 Jan 07; 404(1):498-503. PubMed ID: 21144839
    [Abstract] [Full Text] [Related]

  • 4. Discovery and development of heat shock protein 90 inhibitors as anticancer agents: a review of patented potent geldanamycin derivatives.
    Kim T, Keum G, Pae AN.
    Expert Opin Ther Pat; 2013 Aug 07; 23(8):919-43. PubMed ID: 23641970
    [Abstract] [Full Text] [Related]

  • 5. Cucurbitacin D Is a Disruptor of the HSP90 Chaperone Machinery.
    Hall JA, Seedarala S, Rice N, Kopel L, Halaweish F, Blagg BS.
    J Nat Prod; 2015 Apr 24; 78(4):873-9. PubMed ID: 25756299
    [Abstract] [Full Text] [Related]

  • 6. 17-ABAG, a novel geldanamycin derivative, inhibits LNCaP-cell proliferation through heat shock protein 90 inhibition.
    Lin Z, Peng R, Li Z, Wang Y, Lu C, Shen Y, Wang J, Shi G.
    Int J Mol Med; 2015 Aug 24; 36(2):424-32. PubMed ID: 26059743
    [Abstract] [Full Text] [Related]

  • 7. Structure-based and in silico design of Hsp90 inhibitors.
    Sgobba M, Rastelli G.
    ChemMedChem; 2009 Sep 24; 4(9):1399-409. PubMed ID: 19685544
    [Abstract] [Full Text] [Related]

  • 8. Macrocyclic inhibitors of hsp90.
    Johnson VA, Singh EK, Nazarova LA, Alexander LD, McAlpine SR.
    Curr Top Med Chem; 2010 Sep 24; 10(14):1380-402. PubMed ID: 20536417
    [Abstract] [Full Text] [Related]

  • 9. Design, synthesis, and structure--activity relationships for chimeric inhibitors of Hsp90.
    Shen G, Wang M, Welch TR, Blagg BS.
    J Org Chem; 2006 Sep 29; 71(20):7618-31. PubMed ID: 16995666
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Targeting heat-shock-protein 90 (Hsp90) by natural products: geldanamycin, a show case in cancer therapy.
    Franke J, Eichner S, Zeilinger C, Kirschning A.
    Nat Prod Rep; 2013 Oct 11; 30(10):1299-323. PubMed ID: 23934201
    [Abstract] [Full Text] [Related]

  • 13. Natural Product Inspired N-Terminal Hsp90 Inhibitors: From Bench to Bedside?
    Khandelwal A, Crowley VM, Blagg BSJ.
    Med Res Rev; 2016 Jan 11; 36(1):92-118. PubMed ID: 26010985
    [Abstract] [Full Text] [Related]

  • 14. Inhibitors of the HSP90 molecular chaperone: current status.
    Sharp S, Workman P.
    Adv Cancer Res; 2006 Jan 11; 95():323-48. PubMed ID: 16860662
    [Abstract] [Full Text] [Related]

  • 15. Alleviating neurodegeneration by an anticancer agent: an Hsp90 inhibitor (17-AAG).
    Waza M, Adachi H, Katsuno M, Minamiyama M, Tanaka F, Sobue G.
    Ann N Y Acad Sci; 2006 Nov 11; 1086():21-34. PubMed ID: 17185503
    [Abstract] [Full Text] [Related]

  • 16. Posttranslational modification and conformational state of heat shock protein 90 differentially affect binding of chemically diverse small molecule inhibitors.
    Beebe K, Mollapour M, Scroggins B, Prodromou C, Xu W, Tokita M, Taldone T, Pullen L, Zierer BK, Lee MJ, Trepel J, Buchner J, Bolon D, Chiosis G, Neckers L.
    Oncotarget; 2013 Jul 11; 4(7):1065-74. PubMed ID: 23867252
    [Abstract] [Full Text] [Related]

  • 17. Mechanistic studies on Hsp90 inhibition by ansamycin derivatives.
    Onuoha SC, Mukund SR, Coulstock ET, Sengerovà B, Shaw J, McLaughlin SH, Jackson SE.
    J Mol Biol; 2007 Sep 14; 372(2):287-97. PubMed ID: 17662999
    [Abstract] [Full Text] [Related]

  • 18. Anticancer Inhibitors of Hsp90 Function: Beyond the Usual Suspects.
    Garg G, Khandelwal A, Blagg BS.
    Adv Cancer Res; 2016 Sep 14; 129():51-88. PubMed ID: 26916001
    [Abstract] [Full Text] [Related]

  • 19. Inhibiting protein-protein interactions of Hsp90 as a novel approach for targeting cancer.
    Dutta Gupta S, Bommaka MK, Banerjee A.
    Eur J Med Chem; 2019 Sep 15; 178():48-63. PubMed ID: 31176095
    [Abstract] [Full Text] [Related]

  • 20. Novobiocin and additional inhibitors of the Hsp90 C-terminal nucleotide-binding pocket.
    Donnelly A, Blagg BS.
    Curr Med Chem; 2008 Sep 15; 15(26):2702-17. PubMed ID: 18991631
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 23.